DR FALK PHARMA GMBH has a total of 88 patent applications. It increased the IP activity by 16.0%. Its first patent ever was published in 2008. It filed its patents most often in Australia, EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and machines are FALK PHARMA GMBH, NITEC PHARMA AG and MEDICINES CO.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 11 | |
#2 | EPO (European Patent Office) | 10 | |
#3 | United States | 10 | |
#4 | Canada | 9 | |
#5 | Israel | 6 | |
#6 | South Africa | 6 | |
#7 | Hungary | 5 | |
#8 | WIPO (World Intellectual Property Organization) | 5 | |
#9 | China | 4 | |
#10 | EAPO (Eurasian Patent Organization) | 4 | |
#11 | Montenegro | 4 | |
#12 | Serbia | 4 | |
#13 | Japan | 3 | |
#14 | Ukraine | 2 | |
#15 | Chile | 1 | |
#16 | Hong Kong | 1 | |
#17 | Republic of Korea | 1 | |
#18 | Mexico | 1 | |
#19 | Slovenia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Machines | |
#4 | Measurement | |
#5 | Biotechnology | |
#6 | Basic materials chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Greinwald Roland | 51 |
#2 | Wilhelm Rudolf | 39 |
#3 | Pröls Markus | 31 |
#4 | Wilhelm Rudolph | 24 |
#5 | Prols Markus | 17 |
#6 | Proels Markus | 16 |
#7 | Nacak Tanju | 15 |
#8 | Mohrbacher Ralf | 12 |
#9 | Waenerlund Poulsen Heidi | 10 |
#10 | Fischer Erik | 10 |
Publication | Filing date | Title |
---|---|---|
EP3613414A1 | Pellets with multilayer structure for delayed release of the drug in the distal colon | |
WO2018122086A1 | Enema for rectal application | |
EP3461485A1 | Use of nor-ursodeoxycholic acid for reducing liver fat | |
EP3162362A1 | Optimized high-dose tablet of mesalazine | |
EP3115037A1 | Pharmaceutical preparations for the treatment of inflammatory conditions of the rectum | |
HUE042009T2 | Optimised pharmaceutical formula for the treatment of inflammatory changes of the esophagus | |
EA022886B1 | Method of maintaining remission of ulcerative colitis in patients | |
ME01256B | Pharmaceutical formulation for treating the upper digestive tract |